Literature DB >> 20936376

Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer.

Catherine Leroux1, Elodie Vauléon, Marc Pracht, Yasmina Zoheir, Eveline Boucher, Odile Audrain, Jean-Luc Raoul.   

Abstract

Sorafenib, a new antiangiogenic and antiproliferative agent, is currently used for hepatocellular and renal cell carcinoma. We report here the case of a patient with two cancers, a locally advanced cancer of the piriform sinus and a hepatocellular carcinoma, who was given sorafenib. Tumor response of both cancers might suggest that sorafenib could be effective against head and neck cancer.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20936376     DOI： 10.1007/s12032-010-9708-8

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  10 in total

Review 1.  Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma.

Authors:  Giovana R Thomas; Hari Nadiminti; Jacinto Regalado
Journal:  Int J Exp Pathol       Date:  2005-12       Impact factor: 1.925

2.  Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma.

Authors:  Marialuisa Novi; Ernesto C Lauritano; Anna C Piscaglia; Brunella Barbaro; Maria A Zocco; Maurizio Pompili; Antonio Gasbarrini
Journal:  Am J Gastroenterol       Date:  2009-05-05       Impact factor: 10.864

3.  Oesophageal variceal bleeding in hepatocellular carcinoma with portal vein thrombosis: improved outcome in response to molecular target therapy.

Authors:  S S Wu; H H Yen; C Y Chung
Journal:  Clin Oncol (R Coll Radiol)       Date:  2008-06-16       Impact factor: 4.126

Review 4.  Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation.

Authors:  Phillipe Lothaire; Evandro de Azambuja; Didier Dequanter; Yassine Lalami; Christos Sotiriou; Guy Andry; Gilberto Castro; Ahmad Awada
Journal:  Head Neck       Date:  2006-03       Impact factor: 3.147

5.  Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Authors:  Jan B Vermorken; Ricard Mesia; Fernando Rivera; Eva Remenar; Andrzej Kawecki; Sylvie Rottey; Jozsef Erfan; Dmytro Zabolotnyy; Heinz-Roland Kienzer; Didier Cupissol; Frederic Peyrade; Marco Benasso; Ihor Vynnychenko; Dominique De Raucourt; Carsten Bokemeyer; Armin Schueler; Nadia Amellal; Ricardo Hitt
Journal:  N Engl J Med       Date:  2008-09-11       Impact factor: 91.245

Review 6.  Design and endpoints of clinical trials in hepatocellular carcinoma.

Authors:  Josep M Llovet; Adrian M Di Bisceglie; Jordi Bruix; Barnett S Kramer; Riccardo Lencioni; Andrew X Zhu; Morris Sherman; Myron Schwartz; Michael Lotze; Jayant Talwalkar; Gregory J Gores
Journal:  J Natl Cancer Inst       Date:  2008-05-13       Impact factor: 13.506

7.  Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis.

Authors:  Daichi Takizawa; Satoru Kakizaki; Naondo Sohara; Ken Sato; Hitoshi Takagi; Hirotaka Arai; Kenji Katakai; Akira Kojima; Yutaka Matsuzaki; Masatomo Mori
Journal:  Dig Dis Sci       Date:  2007-03-30       Impact factor: 3.199

8.  Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

Authors:  Christine Elser; Lillian L Siu; Eric Winquist; Mark Agulnik; Gregory R Pond; Soo F Chin; Peggy Francis; Robin Cheiken; James Elting; Angela McNabola; Dean Wilkie; Oana Petrenciuc; Eric X Chen
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

9.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

10.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.